Investigating how T cell co-receptors influence RNA processing
Understanding mechanisms and consequences of T cell co-receptor regulated RNA maturation
['FUNDING_R01'] · ROSWELL PARK CANCER INSTITUTE CORP · NIH-11049109
This study is looking at how certain proteins in T cells help them grow and respond better to infections and cancer, which could lead to improved treatments for patients using immunotherapy.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | ROSWELL PARK CANCER INSTITUTE CORP (nih funded) |
| Locations | 1 site (BUFFALO, UNITED STATES) |
| Trial ID | NIH-11049109 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding how T cell co-receptors, such as CD28, regulate the maturation of RNA in T cells, which is crucial for their ability to respond to infections and tumors. By examining the mechanisms behind RNA splicing and maturation, the study aims to uncover why some immunotherapies targeting these co-receptors fail. The approach involves analyzing the role of specific proteins that influence RNA changes, which could lead to better therapeutic strategies for autoimmune diseases and cancer. Patients may benefit from insights that could improve the effectiveness of immunotherapies.
Who could benefit from this research
Good fit: Ideal candidates include patients with autoimmune diseases or cancers who may benefit from enhanced T cell responses.
Not a fit: Patients with conditions unrelated to T cell function or those not eligible for immunotherapy may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapies for cancer and autoimmune diseases.
How similar studies have performed: Other research has shown promise in targeting T cell co-receptors for immunotherapy, indicating potential for success in this area.
Where this research is happening
BUFFALO, UNITED STATES
- ROSWELL PARK CANCER INSTITUTE CORP — BUFFALO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: OLEJNICZAK, SCOTT HENRY — ROSWELL PARK CANCER INSTITUTE CORP
- Study coordinator: OLEJNICZAK, SCOTT HENRY
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Autoimmune Diseases, autoimmune disorder, autoimmunity disease